| Patient | Sarah Walker |
|---|---|
| Date of birth | 1867-12-23 |
| Identifiers | MRN HR-ET019-SYN-TD; SSN (made up) 000-19-7062 |
| Document date | 1917-04-27 |
| Author | Harriet Okonjo-Bell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin. [S]
Madam Walker returns two weeks after her sick visit for gastroenteritis. The vomiting and diarrhea settled within two days, and she restarted losartan and empagliflozin once she had eaten normally for a day. The potassium and creatinine check due two to four weeks after the losartan increase was not done: she was on a three-week convention tour and her office had booked no laboratory day. The panel planned for the week after the sick visit was also missed when she left on another trip. Her home readings on losartan 100 mg average 134/84. She has had no dizziness, cough, genital itching or muscle aches. She is asking for sauces on the side and no added salt at banquets. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 134/84 on losartan 100 mg |
| Missed checks | Panel after the losartan increase, and the panel a week after the gastroenteritis |
| Gastroenteritis | Resolved; losartan and empagliflozin restarted after a day of normal eating |
| Side effects | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness; weight back up by 0.8 kg since the illness |
| Gastrointestinal | Negative | Bowels normal |
| Cardiovascular | Negative | No ankle swelling |
| Genitourinary | Negative | No burning or genital itching |
| Musculoskeletal | Negative | No muscle aches |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg oral tablet, one tablet each morning | One tablet each morning, at the same home time when traveling | Oral route | 1917-02-23 to 1917-03-09 | completed | S |
| Losartan 100 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 1917-03-09 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet each morning, with sick-day rules | Oral route | 1917-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1917-02-23 | active | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for nausea, for up to two days | Every 8 hours as needed for nausea, up to two days | Oral route | 1917-04-13 to 1917-04-15 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1917-04-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1917-04-27 | Body height | 163 | cm | S |
| 1917-04-27 | Body weight | 77.2 | kg | S |
| 1917-04-27 | Body mass index (BMI) [Ratio] | 29.1 | kg/m2 | S |
| 1917-04-27 | Systolic blood pressure | 136 | mm[Hg] | S |
| 1917-04-27 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1917-04-27 | Heart rate | 76 | /min | S |
| 1917-04-27 | Respiratory rate | 16 | /min | S |
| 1917-04-27 | Body temperature | 36.6 | Cel | S |
| 1917-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1917-04-27 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1917-04-27 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1917-04-27 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 1917-04-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.31 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1917-04-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1912)/1.73 sq M | 50 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 1917-04-27 | Albumin/Creatinine [Mass Ratio] in Urine | 176 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 1917-04-27 | Cholesterol [Mass/volume] in Serum or Plasma | 172 | mg/dL | <=199 mg/dL | Normal | S |
| 1917-04-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 98 | mg/dL | Below 130 mg/dL; lower on treatment by at least 30% | Normal | S |
| 1917-04-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=50 mg/dL | Low | S |
| 1917-04-27 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 1917-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
Vital signs recorded on 1917-04-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 136/86, pulse 76; weight 77.2 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Abdomen | Soft, non-tender |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 1912 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressure | active | confirmed | I12.9 | S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis. |
| Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 1912 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6% | active | confirmed | N18.31 | S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease. |
| Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate) | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 136/86 |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Average 134/84 |
| Examination | Weight and BMI | Every visit | Completed today | 77.2 kg |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 1912, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Deferred | Missed: the panel due two to four weeks after the losartan increase was not done because she was on a three-week tour with no laboratory day booked, and the panel planned a week after the gastroenteritis was missed for another trip. No harm judging by the sick-visit panel (potassium 4.9 mmol/L, creatinine 1.46 mg/dL while volume depleted) and today's results (potassium 4.7 mmol/L, bicarbonate 24 mmol/L, creatinine 1.31 mg/dL, eGFR 50). Corrective action: her office books each laboratory check on a home day before trips are scheduled (INT-012) |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Completed today | 176 mg/g, 39% lower |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Completed today | LDL 98, total cholesterol 172, HDL 48, triglycerides 130 mg/dL; ALT 22 U/L |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | Sick-day rules applied correctly during the gastroenteritis; no side effects; amlodipine added |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Sauces on the side and no added salt at banquets; water on travel days |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026)
Follow-up: Preventive visit in about six weeks. Six-month review in the summer with urine albumin, kidney function and hemoglobin, booked on a home day. Call for ankle swelling, dizziness, or vomiting or diarrhea (hold losartan and empagliflozin). Next scheduled visit 1917-06-08: periodic adult preventive visit. [S]